Silverback Raises U.S. $78.5 Million to Advance SBT6050 into the Clinic for HER2-expressing Solid...
Seattle-based Silverback Therapeutics™, a biopharmaceutical company pioneering a new class of immune-modulating ImmunoTAC™ drug conjugates targeting previously inaccessible disease...
Loretta Itri, M.D., Joins Immunomedics as Chief Medical Officer
Biotech company Immunomedics today confirmed the appointment of Loretta Itri, M.D. as Chief Medical Officer (CMO). In her new...
Navrogen and Levena to Develop Novel ADC for the Treatment of Humoral Immuno-Suppressed Cancers
Biopharmaceutical company Navrogen, specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, have agreed to collaborate...
Zymeworks, Regeneron, Boehringer Ingelheim Pharma and Many Others are Betting on Antibody-Drug-Conjugates
Antibody-Drug -Conjugates (ADCs) have the potential to reduce off-target toxicities in patients by limiting the exposure of normal tissues...
Randall Schatzman, Ph.D. to Lead Growth of Immune-Stimulating Antibody Conjugates at Bolt Biotherapeutics
Veteran Executive Randall Schatzman, Ph.D. has been hired as the new Chief Executive Officer and a member of the...
Single-layer Film Bags vs. Multi-layer Film Bags Biopharmaceutical Manufacturing
Since the early 1970s, single-use, disposable plastic technology for the manufacturing of biopharmaceutical products according to the U.S. Food...
